Semaglutide dosage

Protocol

1. 1

   Reconstitute the vial

   Branded pens (Ozempic, Wegovy) ship pre-filled and require no reconstitution. Compounded vials typically supply lyophilized 2 to 10 mg powder reconstituted with 1 to 2 mL bacteriostatic water; a 0.25 mg starter dose draws 5 to 10 units on a U100 insulin syringe depending on final concentration.

   Open tool →
2. 2

   Measure the dose

   Typical Semaglutide dose is 2.4 mg. Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer weekly (SC); daily (oral Rybelsus). Half-life of 168 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Titrated up every 4 weeks from 0.25 mg to target dose (typically 1.0 to 2.4 mg weekly); not cycled

   Open tool →
5. 5

   Monitor for side effects

   Watch for: nausea; vomiting; diarrhea; constipation. Stop or reduce dose if tolerability breaks down.

Why this dose

Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers.

The typical 2.4 mg dose is the figure most commonly used in published protocols for Semaglutide. Treat the label as a starting point: body weight, training status, sleep, diet, and concurrent medications all shift the effective dose-response curve in real users.

How to administer

Semaglutide is administered via the subcutaneous or oral routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 24 hours after administration. Peak effect lands near 3 days post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: ~7 days terminal half-life, supporting once-weekly SC dosing; oral Rybelsus has shorter effective PK and requires daily dosing

Cycling and tolerance

Titrated up every 4 weeks from 0.25 mg to target dose (typically 1.0 to 2.4 mg weekly); not cycled

Effects to expect at typical dose

• Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
• STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
• Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
• SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
• Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
• GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration

Side effects and interactions

Common side effects

• nausea
• vomiting
• diarrhea
• constipation
• decreased appetite

Notable interactions

• insulin (major): additive hypoglycemia risk; insulin dose typically reduced
• sulfonylureas (glipizide, glyburide) (major): hypoglycemia risk, sulfonylurea dose often reduced
• oral medications (general) (moderate): delayed gastric emptying can alter absorption kinetics
• warfarin (moderate): monitor INR due to altered absorption

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Semaglutide profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

allowed

DEA / Rx

Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021)

Pregnancy

Not recommended; discontinue 2 months before planned pregnancy

Legal status

Prescription only (FDA-approved, EMA-approved)

Do not use if

• personal or family history of medullary thyroid carcinoma
• multiple endocrine neoplasia type 2
• pregnancy
• history of pancreatitis (use caution)

Related research